Latest Market Development News

Thrive Tribe Technologies has repositioned WooBoard and REFFIND towards defence and workforce software, but its FY26 annual report flags a material uncertainty over the company’s ability to continue as a going concern. The pivot follows a $3.66 million loss, $2.57 million operating cash outflow and another $1 million placement after year-end.

Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.

Memphasys has signed a three-year exclusive distribution agreement covering the Czech Republic, Slovakia and Kazakhstan, with minimum purchases worth approximately A$674,000. The deal expands Felix’s European footprint while adding dedicated commercial leadership in the region.

Microba Life Sciences delivered a mixed FY26, with overall revenue slipping 5.8% to $14.76 million and a statutory loss widening 38.7% to $20.7 million. The company’s strategic pivot to core microbiome testing paid off with a 92% surge in core testing revenue and record test volumes in Australia and the UK. Despite the headline loss, underlying loss improved 11% thanks to cost cuts and AI-driven efficiencies. Microba is gearing up for the October launch of its GI Navigator diagnostic and targeting cash flow break-even on a run-rate basis in calendar 2027.

Wide Open Agriculture cut its loss to $3.64 million in FY2026 as it pivots from owning manufacturing to a capital-light contract model, while securing global commercial traction for its lupin-based ingredients.

Saluda Medical delivered FY26 revenue of US$90.2 million, beating guidance with strong US and international growth, while reporting a flat net loss of US$149.6 million amid ongoing heavy investment. The company’s FDA approval of its CAP24 paddle lead opens a new US surgical market segment.

Skellerup Holdings delivered a tenth consecutive year of EBIT growth with a 14% rise to NZD 89.3 million and expanded its climate initiatives, reporting a 24% jump in net profit to NZD 67.7 million.

NZX Limited reported a robust first half of 2026 with operating earnings up 9.4% and net profit rising 18%. The exchange strengthened its funds management and wealth administration arms, relaunched equity derivatives, and declared a higher interim dividend. A new CEO is set to take the helm in September.

EAU Lithium, a subsidiary of Cosmos Exploration, has signed a strategic Master Services Agreement with VULTEC, the German technology arm of Vulcan Energy Resources, to advance lithium extraction projects in Bolivia using cutting-edge direct lithium extraction technology.

Rhythm Biosciences bolstered its financial position with a $5.2 million option underwriting while accelerating commercial adoption of its ColoSTAT® colorectal cancer test and advancing geneType™ partnerships internationally in Q4 FY26.

Lunnon Metals boosts cash to $22.2 million as Lady Herial mining wraps up, launching a record $13 million exploration budget targeting up to 2.4 million ounces of gold at Foster-Baker.

Saluda Medical capped FY26 with a 28% revenue surge, beating guidance at US$90.2 million, while FDA approval for its CAP24 paddle lead opens a new US surgical market segment.